Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Goodwill (2022 - 2024)

Neurocrine Biosciences' Goodwill history spans 3 years, with the latest figure at $5.7 million for Q4 2024.

  • For Q4 2024, Goodwill fell 1.72% year-over-year to $5.7 million; the TTM value through Dec 2024 reached $5.7 million, down 1.72%, while the annual FY2024 figure was $5.7 million, 1.72% down from the prior year.
  • Goodwill reached $5.7 million in Q4 2024 per NBIX's latest filing, down from $6.1 million in the prior quarter.
  • In the past five years, Goodwill ranged from a high of $6.1 million in Q3 2024 to a low of $5.4 million in Q4 2022.
  • Average Goodwill over 3 years is $5.7 million, with a median of $5.7 million recorded in 2023.
  • The largest YoY upside for Goodwill was 10.91% in 2024 against a maximum downside of 1.72% in 2024.
  • A 3-year view of Goodwill shows it stood at $5.4 million in 2022, then increased by 7.41% to $5.8 million in 2023, then dropped by 1.72% to $5.7 million in 2024.
  • Per Business Quant, the three most recent readings for NBIX's Goodwill are $5.7 million (Q4 2024), $6.1 million (Q3 2024), and $5.7 million (Q2 2024).